ArticleJournal of human hypertension2010
Switching of antihypertensive drugs among 93,286 Chinese patients: a cohort study.
Article in Journal of human hypertension, 2010. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 7 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
7 citing papers in PubMed.
- Factors influencing drug switching and changes in low-density lipoprotein-cholesterol levels with atorvastatin: a real-world observational study.Lipids in health and disease · 2023Observational
- Hypertension: sex-related differences in drug treatment, prevalence and blood pressure control in primary care.Journal of human hypertension · 2023Review
- Antihypertensive Prescription Pattern and Compliance to JNC 7 and JNC 8 at Tertiary Care Government Hospital, Hyderabad, India: A Cross-sectional Retrospective Study.Hospital pharmacy · 2018Article
- Antihypertensive drug treatment changes in the general population: the CoLaus study.BMC pharmacology & toxicology · 2014Article
- Initial antihypertensive prescription and switching: a 5 year cohort study from 250,851 patients.PloS one · 2013Article
- Predictors of switching from beta-blockers to other anti-hypertensive drugs: a review of records of 19,177 Chinese patients seen in public primary care clinics in the New Territory East, Hong Kong.Asia Pacific family medicine · 2011Article
- Switching of antihypertensive drugs at Tertiary Care Government Hospital, Hyderabad, India: A cross-sectional retrospective investigation.Indian journal of pharmacologyArticle
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Antihypertensive drug switching induces substantial public health costs. This cohort study evaluated factors associated with switching of antihypertensive agents 180 days after the first date of prescription among ethnic Chinese patients. We included all adult patients aged > or =18 years, who had paid at least two consecutive visits to all public primary care clinics in one large territory of Hong Kong during the study period from January 2004 to June 2007. Binary logistic regression analyses were carried out with antihypertensive drug switching as an outcome variable, while controlling for age, gender, payment status, service types, district of residence, visit types and the number of comorbidities. Among 93,286 eligible patients, 5281 (5.7%) switched their antihypertensive prescriptions to another drug class within 180 days. Patients aged > or =70 years (adjusted odds ratio (aOR) 0.88, P=0.005), male subjects (aOR 0.87, P<0.001) and follow-up visitors (aOR 0.67, P<0.001) were less likely to have their drugs switched. When compared with thaizide diuretics, all other antihypertensive drug classes were associated with a lower likelihood of drug switching (aOR 0.27-0.69, all P<0.001). Closer observations of drug utilization profiles among these patient groups are recommended, and future studies should evaluate the reasons for drug switching.
Indexed as
Identifiers
20054349What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.